ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY (AMPORA)
This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.
Post-Operative Prostate Cancer
RADIATION: Radiotherapy
Rates of Acute Toxicity, Acute grade ≥2 gastrointestinal toxicity (CTCAE v5.0), 2 years
Rates of Acute and Late Toxicity, Acute grade ≥2 genitourinary toxicity (CTCAE v5.0), 2 years|Quality of Life Outcomes, EPIC-26 Questionnaire, 2 years|Quality of Life Outcomes, IPSS Questionnaire, 2 years|Biochemical disease-free survival, Defined as survival until evidence of either biochemical progression (defined as a rise in prostate-specific antigen (PSA) ≥0.2ng/ml above the PSA nadir followed by a sequentially equal or higher value) following postoperative radiotherapy, clinical or radiological progression, initiation of non-protocol systemic therapy, or death from prostate cancer, 2 years|Disease Control Rate, Radiographic and/or histopathological disease control rate, 2 years
This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.